| Date Filed | Type | Description |
| 10/04/2023 |
4
| Rao Veena (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 1,875 shares
@ $0 |
|
| 10/04/2023 |
4
| HANDLEY DANIEL E (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 1,875 shares
@ $0 |
|
| 10/04/2023 |
4
| ST. CLAIR GREGORY SR (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 1,875 shares
@ $0 |
|
| 10/04/2023 |
4
| CHUNG-WELCH NANCY (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 1,875 shares
@ $0 |
|
| 10/04/2023 |
4
| Hawryluk Matthew (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 1,875 shares
@ $0 |
|
| 10/04/2023 |
4
| Nuzum Charles Lee Sr (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 2,605 shares
@ $0 |
|
| 09/27/2023 |
4
| MYERS ROBERT L (CFO) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Exercised 1,667 shares
@ $0
Paid exercise price by delivering 510 shares
@ $2.96, valued at
$1.5k
|
|
| 09/27/2023 |
4
| Nuzum Charles Lee Sr (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Sold 10,000 shares
@ $3.0387, valued at
$30.4k
|
|
| 08/17/2023 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
| 08/10/2023 |
8-K
| Quarterly results|
Docs:
|
"Predictive Oncology Reports Second Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, August 10th, at 5:30pm EDT PITTSBURGH, Aug. 10, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three and six months ended June 30, 2023, and provided a corporate update. The company reported a net loss of $3.9 million on total net revenue of $0.5 million for the second quarter 2023. Q2 2023 and Recent Highlights: Initiated PEDAL-Cancer Research Horizons collabor..." |
|
| 08/10/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
| 07/05/2023 |
4
| Nuzum Charles Lee Sr (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 3,773 shares
@ $0 |
|
| 07/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 07/05/2023 |
4
| Form 4 - Statement of changes in beneficial ownership of securities: |
| 05/15/2023 |
8-K
| Quarterly results|
Docs:
|
"Predictive Oncology Reports First Quarter 2023 Financial Results and Provides Business Update Company to host investor call and webcast today, May 15th, at 5:30pm EDT EAGAN, Minn., May 15, 2023 -- Predictive Oncology , a science driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, CLI laboratory and GMP facility, to accelerate oncologic drug discovery and enable drug development, today reported financial and operating results for the three months ended March 31, 2023, and provided a corporate update. The company reported a net loss of $3.4 million on total net revenue of $0.2 million for the first quarter 2023. Q1 2023 and Recent Highlights: Announced groundbreaking partnership with Cancer Research Ho..." |
|
| 05/15/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
| 05/12/2023 |
4
| Rao Veena (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 1,299 shares
@ $0 |
|
| 05/12/2023 |
3
| Rao Veena (Director) has filed a Form 3 on Predictive Oncology Inc. |
| 05/08/2023 |
8-K
| Regulation FD Disclosure Interactive Data |
| 05/02/2023 |
8-K
| Quarterly results |
| 04/20/2023 |
8-K
| Quarterly results |
| 04/05/2023 |
4
| Hawryluk Matthew (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 18,360 shares
@ $0 |
|
| 04/05/2023 |
4
| ST. CLAIR GREGORY SR (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 25,499 shares
@ $0 |
|
| 04/05/2023 |
4
| CHUNG-WELCH NANCY (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 18,360 shares
@ $0 |
|
| 04/05/2023 |
4
| HANDLEY DANIEL E (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 18,360 shares
@ $0 |
|
| 04/05/2023 |
4
| Nuzum Charles Lee Sr (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 25,499 shares
@ $0 |
|
| 04/05/2023 |
4
| Smith David Stewart (Director) has filed a Form 4 on Predictive Oncology Inc.|
Txns:
| Granted 18,360 shares
@ $0 |
|
| 04/05/2023 |
8-K
| Changes in Registrant's Certifying Accountant, Financial Statements and Exhibits Interactive Data |
| 03/29/2023 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
| 03/21/2023 |
8-K
| Results of Operations and Financial Condition, Financial Statements and Exhibits Interactive Data|
Docs:
|
"Predictive Oncology Reports Year End 2022 Financial Results and Provides Business Update EAGAN, Minn., March 21, 2023 -- Predictive Oncology Inc. , a science-driven company leveraging its proprietary artificial intelligence and machine learning capabilities, extensive biorepository of tumor samples, Clinical Laboratory Improvement Amendments laboratory and Good Manufacturing Practices facility, to accelerate oncology drug discovery and enable drug development, today reported financial and operating results for the year ended December 31, 2022, and provided a corporate update. The company reported a net loss of $25.7 million on total net revenue of $1.5 million for the full year. 2022 Highlights: Successfully completed Discovery 21, establishing proof-of-concept for the PEDAL™ drug discover..." |
|
| 03/21/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
|